Trials / Completed
CompletedNCT00728260
36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds
Post-licensure Safety Surveillance Study of Routine Use of Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®) in Recipients 2 to 10 Years of Age.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,421 (actual)
- Sponsor
- Sanofi Pasteur, a Sanofi Company · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Accepted
Summary
To further characterize the safety profile of Menactra vaccine and to identify any signals of potentially vaccine-related adverse events (AEs) not detected during pre-licensure studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | None administered in this study | N/A in this study |
Timeline
- Start date
- 2005-07-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2008-08-05
- Last updated
- 2015-02-12
- Results posted
- 2015-02-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00728260. Inclusion in this directory is not an endorsement.